OV Management LLC Raises Stock Position in Johnson & Johnson (NYSE:JNJ)

OV Management LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 8.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,572 shares of the company’s stock after purchasing an additional 843 shares during the quarter. OV Management LLC’s holdings in Johnson & Johnson were worth $1,529,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in JNJ. May Hill Capital LLC purchased a new stake in Johnson & Johnson during the 4th quarter worth about $315,000. Invenio Wealth Partners LLC boosted its holdings in Johnson & Johnson by 3.7% in the fourth quarter. Invenio Wealth Partners LLC now owns 3,404 shares of the company’s stock valued at $492,000 after purchasing an additional 120 shares in the last quarter. Lokken Investment Group LLC increased its stake in Johnson & Johnson by 1.7% in the fourth quarter. Lokken Investment Group LLC now owns 15,199 shares of the company’s stock valued at $2,198,000 after purchasing an additional 247 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Johnson & Johnson by 2.8% during the 4th quarter. Geode Capital Management LLC now owns 57,667,920 shares of the company’s stock worth $8,321,881,000 after buying an additional 1,561,036 shares during the last quarter. Finally, Nemes Rush Group LLC boosted its holdings in shares of Johnson & Johnson by 14.6% in the 4th quarter. Nemes Rush Group LLC now owns 55,954 shares of the company’s stock valued at $8,092,000 after buying an additional 7,114 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on JNJ shares. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Raymond James reduced their target price on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Barclays raised their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Tuesday, January 28th. Citigroup reduced their price objective on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $171.33.

Johnson & Johnson Price Performance

Shares of NYSE JNJ opened at $165.89 on Tuesday. The company’s fifty day moving average is $159.06 and its two-hundred day moving average is $156.07. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The firm has a market capitalization of $399.76 billion, a P/E ratio of 24.95, a PEG ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a one year low of $140.68 and a one year high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same period in the prior year, the business posted $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 2.99%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is currently 74.59%.

Insider Buying and Selling

In related news, EVP Timothy Schmid sold 403 shares of the company’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the firm’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at $3,483,645.88. The trade was a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.